MISCELLANEOUS

Poster number

Title

Submitting author

City and Country

280

GENDER DISPARITIES IN QUALITY OF LIFE OF FRENCH PATIENTS ONE YEAR AFTER THE DIAGNOSIS OF LYMPHOMA. A LYSA STUDY

Caroline Besson

Le Chesnay, France

281

Cardiotoxicity risk in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure

Michael Buege

New York, NY, USA

282

Burden of lymphoma in China, 1990−2019: an analysis of Global Burden of Diseases, Injuries, and Risk Factors Study 2019

Weiping Liu

Beijing, China

283

Impact of the COVID-19 pandemic on the diagnosis of mature lymphoid neoplasms in Belgium: Results from the Belgian Cancer Registry

Hélène Antoine-Poirel

Brussels, Belgium

284

Impaired humoral response in lymphoma patients surviving the acute phase of Covid-19

Chiara Cattaneo

Brescia, Italy

285

Multicenter retrospective analysis of risk factors for mortality of COVID-19 infection in patients with lymphoma.

Jan Kořen

Prague, Czech Republic

286

Outcomes of patients with lymphoma and COVID-19: An observational cohort study from GELTAMO Spanish group

Alejandro Martín García-Sancho

Salamanca, Spain

286 bis

Serological responses after SARS-CoV-2 vaccination first dose in patients with lymphoid malignancy: first interim analysis of the UK PROSECO study

Sean H. Lim

Southampton, UK

287

Efficacy and safety of daratumumab for the treatment of multiple myeloma: a series of cochrane reviews

Caroline Hirsch

Cologne, Germany